Ingevity Corporation $NGVT is Simcoe Capital Management LLC’s 7th Largest Position

Simcoe Capital Management LLC lifted its stake in Ingevity Corporation (NYSE:NGVT) by 49.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 933,455 shares of the company’s stock after purchasing an additional 308,520 shares during the period. Ingevity makes up 7.5% of Simcoe Capital Management LLC’s investment portfolio, making the stock its 7th largest holding. Simcoe Capital Management LLC owned 2.56% of Ingevity worth $51,517,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in NGVT. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Ingevity by 311.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 600,380 shares of the company’s stock valued at $23,769,000 after buying an additional 454,579 shares in the last quarter. Boston Partners purchased a new stake in shares of Ingevity during the 3rd quarter worth approximately $14,171,000. American Century Companies Inc. grew its holdings in shares of Ingevity by 15.6% in the 2nd quarter. American Century Companies Inc. now owns 1,707,273 shares of the company’s stock worth $73,566,000 after acquiring an additional 230,525 shares during the period. Harvey Partners LLC grew its holdings in shares of Ingevity by 59.6% in the 2nd quarter. Harvey Partners LLC now owns 572,047 shares of the company’s stock worth $24,650,000 after acquiring an additional 213,547 shares during the period. Finally, Marshall Wace LLP increased its stake in Ingevity by 217.4% in the 3rd quarter. Marshall Wace LLP now owns 228,201 shares of the company’s stock valued at $12,594,000 after purchasing an additional 156,301 shares in the last quarter. 91.59% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have commented on NGVT. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ingevity in a research report on Thursday, January 22nd. Jefferies Financial Group restated a “buy” rating and issued a $82.00 price target on shares of Ingevity in a research report on Thursday, February 26th. Wells Fargo & Company lifted their price target on Ingevity from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Friday, February 27th. BMO Capital Markets reiterated an “outperform” rating and issued a $83.00 price objective on shares of Ingevity in a research report on Monday, March 2nd. Finally, Wall Street Zen cut shares of Ingevity from a “strong-buy” rating to a “buy” rating in a research note on Monday, March 9th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $80.00.

Ingevity Trading Up 0.9%

Shares of Ingevity stock opened at $64.62 on Friday. Ingevity Corporation has a 1 year low of $28.49 and a 1 year high of $77.46. The company has a debt-to-equity ratio of 39.10, a current ratio of 1.33 and a quick ratio of 0.79. The business has a 50 day moving average price of $68.67 and a 200 day moving average price of $59.93. The company has a market capitalization of $2.28 billion, a P/E ratio of -13.90 and a beta of 1.31.

Ingevity (NYSE:NGVT) last announced its earnings results on Wednesday, February 25th. The company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.16). Ingevity had a negative net margin of 13.51% and a positive return on equity of 126.25%. The company had revenue of $255.10 million for the quarter, compared to analyst estimates of $257.27 million. During the same quarter last year, the company posted $0.95 EPS. Ingevity’s quarterly revenue was down 3.2% compared to the same quarter last year. Ingevity has set its FY 2026 guidance at 4.800-5.20 EPS. Sell-side analysts anticipate that Ingevity Corporation will post 4.45 EPS for the current fiscal year.

Ingevity Company Profile

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.